Sertraline

Sertraline

Therapeutic Class
Antidepressant

Subclass
Selective Serotonin Reuptake Inhibitor (SSRI)

Speciality
Psychiatry

Schedule (India)
Schedule H

Routes
Oral

Formulations

• Tablets: 25 mg, 50 mg, 100 mg

• Oral concentrate/solution: NOT AVAILABLE in India

Adult indications

Indications and dosing

Primary Indications (Approved / Standard in India)

1. Major Depressive Disorder (MDD) — Adults

Clinical notes:

• Onset of antidepressant effect: 2-4 weeks

• Trial duration: Minimum 6-8 weeks at therapeutic dose before declaring treatment failure

• Long-term therapy: Continue for 6-12 months after remission if first episode; longer (≥2 years) if recurrent depression

• Taper gradually when discontinuing (reduce by 25-50 mg every 1-2 weeks) to minimize withdrawal symptoms

2. Obsessive-Compulsive Disorder (OCD) — Adults

Clinical notes:

• Higher doses often required for OCD compared to depression

• Response may be delayed; trial for at least 10–12 weeks at adequate dose

• Combine with cognitive-behavioural therapy (CBT) for optimal outcomes

3. Panic Disorder — Adults

Clinical notes:

• Lower starting dose (25 mg) reduces early activation symptoms (jitteriness, anxiety, insomnia)

• Full response may take 8–12 weeks

• Continue for at least 12–24 months after achieving remission

4. Post-Traumatic Stress Disorder (PTSD) — Adults

Clinical notes:

• Evidence-based use per Indian psychiatric practice guidelines

• Combine with trauma-focused psychotherapy

Secondary Indications — Adults (Off-label)

1. Social Anxiety Disorder (Social Phobia) — OFF-LABEL

• Indication: Social anxiety disorder / social phobia

• Starting dose: 25-50 mg once daily

• Titration: Slow increments of 25-50 mg every 1-2 weeks

• Usual effective dose: 50-100 mg/day

• Maximum dose: 200 mg/day (rarely required)

• Duration: Long-term therapy usually required

• Specialist guidance: Psychiatrist consultation recommended

• Evidence basis: International RCTs; widely used in Indian psychiatric practice though not formally CDSCO-approved for this indication

2. Premenstrual Dysphoric Disorder (PMDD) — OFF-LABEL

• Indication: Severe premenstrual mood symptoms meeting PMDD criteria

• Dose: 50-100 mg/day either:

  • Continuous (daily) dosing, OR

  • Luteal phase dosing (start 14 days before expected menses, stop on day 1 of menses)

• Specialist only: Gynecology or psychiatry consultation required

• Evidence basis: International RCTs; limited use in Indian specialist practice

• Clearly marked OFF-LABEL in patient records

3. Generalized Anxiety Disorder (GAD) — OFF-LABEL

• Indication: GAD not responding to first-line agents or when comorbid depression present

• Starting dose: 25-50 mg/day

• Titration: Increase by 25-50 mg every 1-2 weeks

• Usual maintenance dose: 50-100 mg/day

• Maximum dose: 200 mg/day

• Evidence basis: Extension from approved anxiety disorders; Indian psychiatric practice

• Note: Escitalopram has more direct evidence for GAD in India

PAEDIATRIC DOSING (Specialist Only)

use only under paediatric psychiatry or child neurology supervision

Primary Indications (Approved / Standard in India)

1. Obsessive-Compulsive Disorder (OCD)—Age ≥6 years

Children 6-12 years:

Adolescents (≥13 years):

Safety monitoring in children:

• Weekly monitoring for first 4 weeks, then biweekly for 8 weeks, then monthly

• Monitor for: suicidal ideation, behavioural activation (aggression, irritability, agitation), growth parameters (height, weight), sexual development

• Combine with age-appropriate CBT

Secondary Indications - Paediatrics (Off-label)

Paediatric Depression (Age ≥12 years) - OFF-LABEL

• Starting dose: 25-50 mg/day

• Titration: Increase by 25-50 mg every 1-2 weeks based on response

• Usual maintenance dose: 50-100 mg/day

• Maximum dose: 200 mg/day

• Specialist only: Paediatric psychiatrist

• Evidence basis: Limited RCT support; Indian paediatric psychiatry protocols; fluoxetine has stronger paediatric depression evidence

• Clearly marked OFF-LABEL

• Black box warning: Increased risk of suicidal thoughts and behaviour in children and adolescents; close monitoring essential

Age restrictions:

• Not recommended below age 6 years except under paediatric psychiatry specialist supervision with clear rationale

• Below age 12 years for depression: Not recommended; consider psychotherapy first-line

Renal Adjustments

• Mild-to-moderate renal impairment (CrCl ≥30 mL/min or eGFR ≥30 mL/min/1.73m2): No dose adjustment required

• Severe renal impairment (CrCl <30 mL/min or eGFR <30 mL/min/1.73m2): No specific dosing recommendations available. Use with caution; start at 25 mg/day and titrate slowly. Monitor closely for adverse effects (sertraline has minimal renal excretion but may accumulate in severe impairment).

Haemodialysis:

Sertraline is not significantly removed by dialysis. No specific dosing guidance; monitor clinical response and tolerability. Consider lower starting dose (25 mg) and slower titration.

Peritoneal dialysis:

No specific data; use caution similar to haemodialysis.

Hepatic adjustment

Mild hepatic impairment (Child-Pugh A):

No dose adjustment required. Monitor for increased adverse effects.

Moderate hepatic impairment (Child-Pugh B):

• Start at 50% of recommended dose (e.g., 25 mg/day instead of 50 mg)

• Titrate cautiously at longer intervals (every 2 weeks)

• Maximum dose: 100 mg/day (avoid higher doses)

• Monitor liver function periodically

Severe hepatic impairment (Child-Pugh C):

• Avoid use if possible

• If essential and no alternative: specialist hepatology + psychiatry input required

• Start at 25 mg every other day or 25 mg twice weekly

• Titrate very slowly with close monitoring

Mechanism: Sertraline undergoes extensive hepatic metabolism; impaired clearance in liver disease increases risk of accumulation and toxicity.

Contraindications

Absolute contraindications:

• Known hypersensitivity to sertraline or any excipients in the formulation

• Concurrent use with monoamine oxidase inhibitors (MAOIs):

  • Do not use sertraline within 14 days after stopping an MAOI (risk of serotonin syndrome)

  • Do not start an MAOI within 14 days after stopping sertraline (allow washout)

  • Includes: phenelzine, tranylcypromine, isocarboxazid (rare in India), selegiline, rasagiline

• Concurrent use with pimozide (risk of QT prolongation and torsades de pointes; pharmacokinetic interaction via CYP2D6)

• Concurrent use with linezolid or intravenous methylene blue (potent reversible MAOIs; serotonin syndrome risk). Exception: Life-threatening situation requiring linezolid/methylene blue → discontinue sertraline, give linezolid/methylene blue, monitor closely, restart sertraline 24 hours after last dose of linezolid/methylene blue.

• Acute intoxication with alcohol, sedatives, hypnotics, or psychotropic drugs

Cautions

Use with caution and close monitoring in:

• History of seizures or epilepsy — SSRIs lower seizure threshold (dose-dependent); risk higher with rapid dose escalation or high doses

• Bipolar disorder or history of mania/hypomania — risk of switching to manic episode; ensure mood stabilizer in place before starting SSRI

• Bleeding disorders or concurrent anticoagulation/antiplatelet therapy — SSRIs impair platelet function (inhibit serotonin uptake in platelets); increased risk of GI bleeding, especially with NSAIDs, aspirin, warfarin, clopidogrel

• History of GI bleeding — SSRIs increase risk; consider proton pump inhibitor (PPI) co-prescription if on NSAIDs or anticoagulants

• Angle-closure glaucoma — SSRIs can cause pupillary dilation (rare); risk of acute angle-closure attack in predisposed individuals (shallow anterior chamber)

• Hyponatremia / SIADH risk factors — elderly, volume-depleted, diuretic use, chronic kidney disease, hypothyroidism; monitor sodium especially first 4 weeks

• Cardiac disease — sertraline has low cardiac risk among SSRIs but caution in recent MI, unstable angina, significant arrhythmias, congenital long QT syndrome

• Hepatic impairment — see Hepatic Adjustment section

• Renal impairment — see Renal Adjustment section

• Diabetes mellitus — SSRIs may affect glycemic control (usually improve depression-related hyperglycemia, but monitor)

• Suicidal ideation / high suicide risk — close monitoring essential, especially:

  • First 4 weeks of treatment

  • After dose changes

  • In adolescents and young adults (<25 years)

  • Provide emergency contact information; involve family in monitoring

• Concomitant use of serotonergic drugs — tramadol, triptans, tryptophan supplements, St. John's wort, other antidepressants (risk of serotonin syndrome)

• Alcohol use — advise patients to avoid alcohol (potentiates CNS effects)

• History of sexual dysfunction — SSRIs commonly cause sexual side effects; discuss proactively

Pregnancy

Lactation

Elderly

Starting dose:

• 25 mg once daily (50% of standard adult starting dose)

• Elderly more sensitive to adverse effects (CNS, GI, hyponatremia)

Titration:

• Increase slowly: 25 mg increments every 2 weeks (slower than standard weekly titration)

• Assess response and tolerability at each step

• Many elderly patients respond to lower doses (25-50 mg/day)

Usual maintenance dose:

25-100 mg/day (often lower end of range sufficient)

Maximum dose:

• Generally, limit to 150 mg/day in elderly (avoid 200 mg unless compelling indication and good tolerability)

Extra risks in elderly:

• Hyponatremia / SIADH: Most common serious adverse effect in elderly on SSRIs

  • Risk factors: age >65 years, female, low body weight, diuretic use, baseline low sodium

  • Monitor serum sodium at baseline, 2 weeks, 4 weeks, then as clinically indicated

  • Symptoms: confusion, headache, lethargy, falls, seizures

  • Management: Stop sertraline, fluid restriction, specialist input; consider switching to mirtazapine if antidepressant still needed

• Falls: Increased risk due to:

  • Dizziness, orthostatic hypotension (rare with sertraline but possible)

  • Hyponatremia causing confusion

  • Sedation (especially if combined with benzodiazepines)

  • Advise fall precautions; review polypharmacy

• Cognitive impairment: Ensure adequate trial of antidepressant before attributing cognitive symptoms to depression vs. dementia; SSRIs generally do not worsen cognition but severe hyponatremia can mimic dementia

• Bleeding risk: Higher baseline risk of GI bleeding in elderly; further increased with SSRIs + NSAIDs / aspirin / anticoagulants

  • Consider PPI co-prescription if on antiplatelet / anticoagulant therapy

• Drug interactions: Polypharmacy common; review medication list carefully (see interactions sections)

• Renal and hepatic function: Age-related decline; monitor renal function (eGFR) and hepatic function; adjust dose if impaired (see respective sections)

Monitoring in elderly:

• Baseline: Sodium, renal function, liver function, medications review, falls risk

• 2 weeks: Sodium, clinical response, tolerability, suicidal ideation

• 4 weeks: Sodium, clinical response

• Ongoing: Sodium if symptoms, clinical response monthly until stable, then every 3-6 months

Major drug interactions

1. Monoamine Oxidase Inhibitors (MAOIs)

• Drugs: Phenelzine, tranylcypromine, isocarboxazid (rare in India), selegiline, rasagiline, linezolid, intravenous methylene blue

• Mechanism: Combined serotonin reuptake inhibition + MAO inhibition → serotonin syndrome (excess serotonergic activity)

• Risk: Life-threatening serotonin syndrome (hyperthermia, rigidity, myoclonus, autonomic instability, altered consciousness, seizures, death)

• Management: CONTRAINDICATED. Do not use sertraline within 14 days after stopping MAOI. Do not start MAOI within 14 days after stopping sertraline. Exception for linezolid/methylene blue: see Contraindications section.

2. Pimozide

• Mechanism: Sertraline inhibits CYP2D6, reducing pimozide metabolism; both drugs prolong QT interval → additive risk

• Risk: QT prolongation, torsades de pointes, sudden cardiac death

• Management: CONTRAINDICATED — do not use together

3. Serotonergic Drugs (Serotonin Syndrome Risk)

• Drugs: Tramadol, Triptans (sumatriptan, rizatriptan, etc.), Tryptophan supplements, St. John's wort, Other antidepressants (SNRIs: venlafaxine, duloxetine; TCAs; mirtazapine; MAOIs), Lithium, Fentanyl (high doses), Dextromethorphan (high doses), Amphetamines, methylphenidate

• Mechanism: Additive serotonergic activity → serotonin syndrome

• Risk: Serotonin syndrome (mild: tremor, diarrhea, sweating; severe: hyperthermia, rigidity, seizures, rhabdomyolysis, death)

• Management:

  • Avoid combination if possible

  • If essential (e.g., triptan for migraine in patient on sertraline):

    • Use lowest effective triptan dose

    • Monitor closely for serotonin syndrome (especially first dose)

    • Educate patient on symptoms: agitation, confusion, rapid heart rate, dilated pupils, tremor, sweating, diarrhea, muscle rigidity — seek immediate care if occurs

  • Tramadol: Consider alternative analgesic (paracetamol, NSAIDs, opioids without serotonergic activity); if tramadol essential, use lowest dose and monitor

  • Lithium: Used together in refractory depression (augmentation strategy) but requires specialist psychiatry supervision and therapeutic lithium monitoring

4. Anticoagulants and Antiplatelet Agents

• Drugs: Warfarin, heparin, dabigatran, rivaroxaban, apixaban, aspirin, clopidogrel, prasugrel, ticagrelor

• Mechanism: SSRIs inhibit serotonin uptake into platelets → impaired platelet aggregation → increased bleeding risk; additive with anticoagulants/antiplatelets. Sertraline also may inhibit warfarin metabolism (CYP2C9, protein binding displacement) → increased INR.

• Risk: Increased risk of bleeding (GI bleeding most common; also intracranial hemorrhage, ecchymoses)

• Management: Not contraindicated but requires close monitoring

  • Warfarin: Check INR more frequently after starting/stopping sertraline or dose changes; may need warfarin dose adjustment

  • Aspirin / clopidogrel: If used for cardiovascular indications (post-MI, post-stent), benefits usually outweigh bleeding risk; continue but:

    • Monitor for bleeding (GI symptoms, bruising, hematuria)

    • Consider PPI co-prescription (omeprazole, pantoprazole) to reduce GI bleeding risk

    • Educate patient on bleeding warning signs

  • NSAIDs: See Moderate Interactions; similar bleeding risk

5. QT-Prolonging Drugs (Additive QT Prolongation)

• Drugs: Amiodarone, sotalol, quinidine, procainamide, haloperidol, droperidol, chlorpromazine, methadone, ondansetron (high dose IV), azithromycin, clarithromycin, fluoroquinolones (moxifloxacin), antifungals (fluconazole, ketoconazole)

• Mechanism: Sertraline has low intrinsic QT prolongation risk (less than citalopram, escitalopram) but at high doses (>200 mg) or in predisposed patients (electrolyte abnormalities, cardiac disease, genetic long QT), risk exists; additive with other QT-prolonging drugs

• Risk: QT prolongation → torsades de pointes (polymorphic ventricular tachycardia)

• Management:

  • Use with caution; avoid high-dose sertraline (>150 mg) if on QT-prolonging drug

  • Baseline ECG if multiple risk factors or on known QT-prolonging drug

  • Correct electrolytes (K+, Mg2+, Ca2+) before and during therapy

  • Monitor ECG if symptoms (palpitations, syncope, presyncope)

  • Consider alternative antidepressant with lower QT risk (mirtazapine, bupropion — not available in India) or alternative for the other QT-prolonging drug if feasible

6. CYP2D6 Substrates with Narrow Therapeutic Index

• Drugs: Metoprolol, propafenone, flecainide, thioridazine (rarely used), risperidone, aripiprazole, atomoxetine (not available in India), codeine, tamoxifen

• Mechanism: Sertraline is a moderate inhibitor of CYP2D6 → reduces metabolism of CYP2D6 substrates → increased plasma levels → toxicity risk

• Risk: Depends on drug:

  • Beta-blockers (metoprolol): Excessive bradycardia, hypotension, heart block

  • Antiarrhythmics (propafenone, flecainide): Proarrhythmia

  • Antipsychotics (risperidone, thioridazine): Extrapyramidal symptoms, QT prolongation (thioridazine)

  • Tamoxifen: Reduced conversion to active metabolite (endoxifen) → reduced breast cancer efficacy (controversial; avoid if possible in tamoxifen-treated patients)

  • Codeine: Reduced conversion to morphine → reduced analgesic efficacy (not a safety issue but efficacy concern)

• Management:

  • Metoprolol / propafenone / flecainide: Use alternative SSRI with minimal CYP2D6 inhibition (escitalopram, citalopram) if possible; if sertraline necessary, monitor heart rate, BP, ECG; may need dose reduction of beta-blocker/antiarrhythmic

  • Risperidone: Monitor for extrapyramidal symptoms; may need dose reduction

  • Tamoxifen: Avoid sertraline in breast cancer patients on tamoxifen; use venlafaxine (hot flashes) or escitalopram (depression) with less CYP2D6 inhibition

  • Codeine: Use alternative opioid (morphine, oxycodone, tramadol — though tramadol has serotonin syndrome risk, see above)

Moderate drug interactions

1. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)

• Drugs: Ibuprofen, diclofenac, naproxen, aceclofenac, etoricoxib, celecoxib

• Mechanism: Additive antiplatelet effect (SSRI + NSAID) → increased GI bleeding risk

• Risk: Upper GI bleeding (absolute risk increase ~2-4 per 1000 patient-years)

• Management:

  • Use together with caution

  • Prescribe PPI (omeprazole 20mg, pantoprazole 40mg) if NSAID needed chronically

  • Use lowest effective NSAID dose for shortest duration

  • Consider selective COX-2 inhibitor (celecoxib, etoricoxib) - lower GI risk but still some risk

  • Educate patient on GI bleeding symptoms: black stools, hematemesis, severe abdominal pain → seek immediate care

  • Prefer alternative analgesic if possible (paracetamol)

2. Benzodiazepines

• Drugs: Alprazolam, clonazepam, lorazepam, diazepam

• Mechanism: Pharmacodynamic interaction (additive CNS depression); sertraline may inhibit metabolism of some benzodiazepines (CYP3A4 substrates like alprazolam, diazepam - weak inhibition)

• Risk: Increased sedation, dizziness, psychomotor impairment, falls (especially elderly)

• Management:

  • Can be used together (often co-prescribed for anxiety in India)

  • Use lowest effective benzodiazepine dose

  • Monitor for excessive sedation, especially first 2 weeks

  • Taper benzodiazepine gradually once SSRI effect established (4-6 weeks)

  • Avoid long-term benzodiazepine use; goal is short-term anxiolytic bridge while SSRI takes effect

3. Antiepileptic Drugs (Enzyme Inducers)

• Drugs: Phenytoin, carbamazepine, phenobarbital, primidone

• Mechanism: CYP enzyme induction (CYP3A4, CYP2C19, others) → increased sertraline metabolism → reduced sertraline levels → potential loss of efficacy

• Risk: Treatment failure, depression relapse

• Management:

  • Monitor clinical response closely

  • May need higher sertraline dose (titrate to 150-200 mg or higher if tolerated and needed)

  • Check sertraline levels if available (not routinely available in India; use clinical response as guide)

  • Consider alternative antidepressant less affected by enzyme induction (e.g., mirtazapine) if treatment failure despite dose increase

Note: Valproate, lamotrigine, levetiracetam do not significantly affect sertraline levels (no enzyme induction)

4. Rifampicin (Rifampin)

• Mechanism: Potent CYP enzyme inducer → markedly increases sertraline metabolism → reduced sertraline levels

• Risk: Loss of antidepressant efficacy during TB treatment

• Management:

  • Anticipate need for higher sertraline dose during rifampicin co-administration

  • Monitor depression symptoms closely

  • May need to double sertraline dose or more (titrate based on response)

  • Consider alternative antidepressant (e.g., mirtazapine, escitalopram — though all affected to some degree)

  • After stopping rifampicin: gradually reduce sertraline dose back to pre-rifampicin level over 2-4 weeks (rifampicin enzyme induction wears off over ~2 weeks)

5. Alcohol

• Mechanism: Pharmacodynamic interaction; additive CNS depression

• Risk: Increased sedation, impaired judgment, worsening depression

• Management:

  • Advise patients to avoid or minimize alcohol consumption while on sertraline

  • Educate that alcohol can worsen depression and reduce medication efficacy

  • Not a pharmacokinetic interaction (sertraline does not significantly alter alcohol metabolism)

6. Cimetidine

• Mechanism: Cimetidine inhibits CYP2C19, CYP2D6, CYP3A4 → reduces sertraline clearance → increased sertraline levels

• Risk: Increased SSRI side effects (nausea, diarrhea, agitation, tremor)

• Management:

  • Monitor for increased sertraline side effects if cimetidine started

  • Consider alternative H2-blocker (ranitidine, famotidine) or PPI (no interaction)

  • May need to reduce sertraline dose if significant side effects occur

7. Digoxin

• Mechanism: Unclear; possible pharmacokinetic interaction

• Risk: Digoxin toxicity (though evidence conflicting; generally considered low risk)

• Management:

  • Monitor digoxin levels if available, or monitor clinically for digoxin toxicity (nausea, vomiting, visual changes, arrhythmias)

  • Routine ECG monitoring for bradycardia, AV block

8. Antipsychotics (Non-CYP2D6 Substrates)

• Drugs: Olanzapine, quetiapine, haloperidol (substrate but wide therapeutic index)

• Mechanism: Pharmacodynamic (additive sedation, possible additive QT prolongation with some agents)

• Risk: Sedation, orthostatic hypotension; QT prolongation (especially haloperidol, quetiapine high dose)

• Management:

  • Can be used together (commonly combined in depression with psychotic features, bipolar depression, treatment-resistant depression)

  • Monitor for sedation, orthostatic vital signs

  • ECG if using haloperidol or high-dose quetiapine

Common adverse effects

Incidence ≥1-10%; generally mild and transient:

• Nausea (most common, especially first 2 weeks; take with food to minimize; usually resolves)

• Diarrhea / loose stools (common; usually mild; rarely requires discontinuation)

• Headache (usually mild; manage with paracetamol)

• Insomnia / sleep disturbance (take in morning to minimize; can also cause drowsiness in some patients)

• Somnolence / drowsiness (less common with sertraline than some SSRIs; take at bedtime if occurs)

• Dizziness (usually mild; advise caution with activities requiring alertness initially)

• Agitation, anxiety, nervousness (especially first 2 weeks; start with low dose in anxiety disorders to minimize; usually transient)

• Tremor (fine tremor of hands; usually mild; dose-related)

• Dry mouth (encourage hydration, sugar-free gum/candy, saliva substitutes)

• Sexual dysfunction: (20–40% incidence, often underreported)

  • Delayed ejaculation / anorgasmia (most common)

  • Decreased libido

  • Erectile dysfunction

  • Reduced genital sensitivity

  • Management: Dose reduction if possible, drug holiday (skip doses on weekends — not generally recommended due to withdrawal risk), add antidote (sildenafil for ED, bupropion — not available in India; consider switching to mirtazapine or agomelatine if severe and persistent)

• Increased sweating / hyperhidrosis (especially night sweats)

• Fatigue / asthenia

• Decreased appetite / weight loss (early; can shift to weight gain with long-term use)

• Dyspepsia / indigestion

Serious adverse effects

Rare but clinically important; requires immediate action:

1. Serotonin Syndrome

• Incidence: Rare; higher risk with drug combinations (MAOIs, tramadol, triptans, other serotonergic drugs) or overdose

• Presentation: Triad of:

  • Autonomic instability: Hyperthermia, tachycardia, labile BP, diaphoresis, mydriasis

  • Neuromuscular abnormalities: Myoclonus, hyperreflexia, rigidity, tremor, clonus (especially lower extremities)

  • Mental status changes: Agitation, confusion, delirium, coma

• Severity: Mild (tremor, diarrhea, tachycardia) to life-threatening (hyperthermia >41°C, seizures, rhabdomyolysis, DIC, death)

• Management:

  • Discontinue sertraline and all serotonergic drugs immediately

  • Supportive care: IV fluids, cooling, benzodiazepines (lorazepam, diazepam) for agitation/seizures

  • ICU admission if severe

  • Specific antidote: Cyproheptadine (serotonin antagonist) 12 mg initial dose, then 2 mg q2h until symptoms improve (max 32 mg/day) — not widely available in India; supportive care mainstay

2. Suicidal Ideation and Behaviour

• Incidence: Black box warning (US FDA); increased risk in children, adolescents, young adults <25 years, especially first 4 weeks of treatment or after dose changes

• Mechanism: "Activation syndrome" — SSRI may increase energy/motivation before improving mood, allowing suicidal ideation to be acted upon; or disinhibition effect

• Risk factors: Age <25 years, previous suicide attempt, severe depression, comorbid anxiety/agitation, substance abuse, impulsivity

• Management:

  • Close monitoring especially weeks 1–4 and after dose changes: weekly visits or phone contact

  • Involve family/caregivers in monitoring; provide emergency contact numbers

  • Assess suicidality at each visit (passive ideation, active ideation, plan, intent, access to means)

  • Prescribe limited quantities initially (7–14 day supply) to limit overdose potential

  • If active suicidal ideation develops: Immediate psychiatric consultation, consider hospitalization, discontinue sertraline (gradually if safe to do so), consider ECT or alternative treatment

  • Document risk assessment and safety plan in medical record

3. Seizures

• Incidence: Rare (<0.1%); dose-related

• Risk factors: History of epilepsy, structural brain lesion, metabolic disorder, alcohol/benzodiazepine withdrawal, concomitant medications lowering seizure threshold, rapid dose escalation, high doses

• Management:

  • Discontinue sertraline if seizure occurs and no other clear cause

  • Neurologic evaluation (EEG, imaging if new-onset seizure)

  • Do not rechallenge with sertraline if clear temporal relationship

  • Consider alternative antidepressant with lower seizure risk (escitalopram, mirtazapine)

4. Hyponatremia / SIADH

• Incidence: 0.5-2%; much higher in elderly (up to 10%)

• Mechanism: SSRIs enhance ADH release or sensitivity → water retention → dilutional hyponatremia

• Risk factors: Age >65 years, female, low body weight, diuretic use (especially thiazides), baseline low sodium, first 4 weeks of treatment

• Presentation: Mild (Na+ 125-135 mEq/L): asymptomatic or mild confusion, headache, nausea. Severe (Na+ <120 mEq/L): confusion, seizures, coma

• Management:

  • Monitor sodium at baseline, 2 weeks, 4 weeks (especially elderly)

  • If hyponatremia develops:

    • Mild (125-135 mEq/L), asymptomatic: Continue sertraline, fluid restriction, monitor sodium closely

    • Moderate (120-125 mEq/L) or symptomatic: Discontinue sertraline, fluid restriction, specialist input (endocrinology/nephrology)

    • Severe (<120 mEq/L): Discontinue sertraline, hospital admission, careful sodium correction (avoid overly rapid correction → osmotic demyelination syndrome)

  • Alternative antidepressant if severe or recurrent hyponatremia: Consider mirtazapine (lower SIADH risk)

5. QT Prolongation and Torsades de Pointes

• Incidence: Very rare; sertraline has lower QT risk than citalopram/escitalopram

• Risk factors: High dose (>200 mg), baseline QT prolongation, congenital long QT syndrome, electrolyte abnormalities (hypokalemia, hypomagnesemia), bradycardia, concomitant QT-prolonging drugs, female sex

• Management:

  • Baseline ECG if risk factors present

  • Correct electrolytes (K+ >4.0 mEq/L, Mg2+ >2.0 mEq/L)

  • Monitor ECG if symptoms (syncope, palpitations)

  • If QTc >500 msec or increase >60 msec from baseline: Discontinue sertraline; cardiology consultation

  • Alternative antidepressant: Mirtazapine (no QT effect)

6. Bleeding Events (GI, Intracranial)

• Incidence: 1-2% for clinically significant GI bleeding; intracranial hemorrhage very rare (but higher with concurrent anticoagulants)

• Risk factors: Age >65 years, history of GI bleeding/peptic ulcer, concurrent NSAIDs/aspirin/anticoagulants, alcohol use, H. pylori infection

• Management:

  • See Major/Moderate Interactions for anticoagulant/antiplatelet use

  • Co-prescribe PPI if high risk

  • If GI bleeding occurs: Discontinue sertraline, gastroenterology consultation, endoscopy if indicated

  • Can rechallenge after healing if benefits outweigh risks and risk factors modified (add PPI, stop NSAID, etc.)

7. Mania / Hypomania (Bipolar Switch)

• Incidence: 1-2% in undiagnosed bipolar disorder; higher in bipolar I than bipolar II

• Risk factors: Personal or family history of bipolar disorder, prior manic/hypomanic episode, early-onset depression (<25 years), psychotic depression, antidepressant-induced activation

• Presentation: Elevated mood, decreased need for sleep, pressured speech, grandiosity, increased goal-directed activity, impulsivity, irritability

• Management:

  • Discontinue sertraline (or reduce to lowest effective dose)

  • Start mood stabilizer (lithium, valproate) or atypical antipsychotic (quetiapine, olanzapine)

  • Psychiatric consultation

  • Re-evaluate diagnosis (may be bipolar disorder, not unipolar depression)

  • Avoid SSRI monotherapy in bipolar disorder (use mood stabilizer ± antipsychotic; add SSRI cautiously only if needed for bipolar depression and on mood stabilizer)

8. Stevens-Johnson Syndrome (SJS) / Toxic Epidermal Necrolysis (TEN)

• Incidence: Extremely rare (case reports)

• Presentation: Severe mucocutaneous reaction; prodrome of fever, malaise; then painful erythematous rash, bullae, mucosal involvement (oral, ocular, genital), skin sloughing

• Management:

  • Discontinue sertraline immediately if SJS/TEN suspected

  • Emergency dermatology + ophthalmology consultation

  • Hospital admission (burn unit or ICU)

  • Do NOT rechallenge with sertraline or other SSRIs

  • Report to pharmacovigilance (CDSCO)

9. Angle-Closure Glaucoma (Acute)

• Incidence: Very rare

• Mechanism: SSRIs may cause pupillary dilation → angle closure in predisposed individuals (shallow anterior chamber, hyperopia)

• Presentation: Sudden eye pain, blurred vision, halos around lights, headache, nausea, vomiting

• Management:

  • Ophthalmology emergency — immediate referral

  • Stop sertraline

  • Treatment: Laser iridotomy (definitive), topical medications to lower intraocular pressure

  • Can resume sertraline after iridotomy if needed

10. Withdrawal Syndrome (SSRI Discontinuation Syndrome)

• Incidence: 20-50% if stopped abruptly; less common with sertraline (longer half-life) than paroxetine but still occurs

• Presentation: Flu-like symptoms (fatigue, myalgia, nausea), dizziness, paresthesias ("brain zaps"), insomnia, vivid dreams, irritability, anxiety, low mood (not recurrence of depression; occurs within days of stopping)

• Prevention:

  • Always taper sertraline when discontinuing (reduce by 25-50 mg every 1-2 weeks)

  • Slower taper if on high dose or long duration

  • Educate patients not to stop abruptly

• Management if necessary:

  • Reinstate sertraline at previous dose (symptoms resolve within 24-48 hours)

  • Symptomatic treatment: Fluoxetine single dose (20 mg) can alleviate symptoms due to long half-life (self-tapering effect)

Monitoring requirements

Baseline (Before Starting Sertraline):

• Clinical assessment:

  • Psychiatric history: Diagnosis (confirm depression/anxiety disorder), severity (depression rating scale: PHQ-9, HAM-D if available), previous treatments and response, duration of illness

  • Suicide risk assessment (ideation, plan, intent, previous attempts, access to means, protective factors)

  • Substance use history (alcohol, drugs)

  • Family psychiatric history (especially bipolar disorder, suicide)

  • Medical history: Cardiovascular disease, seizures, liver disease, renal disease, bleeding disorders, glaucoma

  • Current medications (drug interaction check)

  • Mental status examination

• Laboratory / Investigations (selective based on risk factors):

  • Serum sodium (especially if elderly, on diuretics, or baseline symptoms)

  • Liver function tests if baseline liver disease suspected

  • Renal function (serum creatinine, eGFR) if elderly or renal disease

  • ECG if:

    • Age >65 years with cardiac risk factors

    • History of cardiac disease (arrhythmias, congenital long QT, recent MI)

    • On QT-prolonging drugs

    • Electrolyte abnormalities (hypokalemia, hypomagnesemia) → correct before starting

  • Pregnancy test if woman of childbearing potential (discuss risks if positive)

After Initiation / Dose Change:

• Week 1-2:

  • Clinical review (in-person or phone contact):

    • Tolerability: Nausea, diarrhea, headache, insomnia, activation/agitation

    • Suicidality assessment (especially age <25 years)

    • Adherence

    • Reassurance that full effect takes 4-6 weeks

  • Serum sodium at 2 weeks if elderly or high risk

• Week 4:

  • Clinical review:

    • Early response (25-50% improvement suggests likely full response)

    • Side effects (should be improving if transient; assess sexual dysfunction proactively)

    • Suicidality

  • Serum sodium at 4 weeks if elderly or high risk, or if new confusion/headache

• Week 6-8:

  • Assess therapeutic response:

    • Use structured tool (PHQ-9, HAM-D) to quantify improvement

    • Adequate trial = 6-8 weeks at therapeutic dose (≥50 mg for depression, 100-200 mg for OCD)

    • If inadequate response: Increase dose or consider switch/augmentation (psychiatry consultation)

  • Side effects management

  • Plan long-term therapy if responding

Long-term Monitoring (Chronic Use):

*Every 1-3 months initially, then every 3-6 months once stable:*

• Clinical response and symptom monitoring (PHQ-9 or similar)

• Functional status (return to work, social activities, relationships)

• Adherence

• Side effects:

  • Sexual dysfunction (assess at every visit; often not volunteered)

  • Weight changes (can cause weight gain long-term in some patients; monitor BMI)

  • Emotional blunting / apathy (anhedonia despite depression remission — "SSRI-induced apathy syndrome"; may need dose reduction or switch)

• Serum sodium annually if elderly, or if new symptoms suggestive of hyponatremia

Before discontinuation (when appropriate):

• Ensure sustained remission (≥6-12 months symptom-free for first episode; longer for recurrent)

• Psychosocial stability (no major stressors, good support system)

• Patient agreement and understanding of relapse risk

• Gradual taper plan (reduce by 25-50 mg every 1-2 weeks; slower if high dose or long duration)

• Close monitoring during taper and first 6 months after discontinuation (highest relapse risk)

No routine monitoring required:

• Liver function tests (unless baseline liver disease or new hepatic symptoms)

• Renal function (unless baseline renal disease or elderly with decline in GFR)

• ECG (unless baseline indication or new cardiac symptoms)

• Drug levels (sertraline therapeutic drug monitoring not routinely available or recommended in India)

Brands in India

Common brands (sertraline hydrochloride):

• Zoloft (Pfizer) — innovator brand; less commonly available/prescribed in India

• Daxid (Abbott India / Pfizer marketed previously)

• Serlift (Torrent Pharmaceuticals) — widely available

• Zosert (Sun Pharmaceutical)

• Sertafine (Intas Pharmaceuticals)

• Sertral (Unichem Laboratories)

• Serta (Intas)

• Sertima (Lupin)

• Asentra (Ranbaxy / Sun Pharma)

• Serenata (Cipla)

Fixed-dose combinations (FDCs):

• Sertraline + Clonazepam (various brands):

  • Example: Zosert-Plus (sertraline 50 mg + clonazepam 0.5 mg)

  • Not first-line; used in some Indian psychiatric practice for comorbid anxiety/insomnia

  • Concerns: Benzodiazepine dependence risk; prefer sertraline monotherapy with short-term benzodiazepine if needed, then taper benzodiazepine

  • CDSCO approval status: Many sertraline FDCs with benzodiazepines are approved, but rationality debated

Note on FDCs: Indian guidelines and global best practice recommend monotherapy with sertraline for depression/anxiety disorders. Benzodiazepines may be added short-term for severe anxiety but should be separate prescriptions (not FDC) to allow independent titration and tapering.

Price range (INR)

Approximate retail prices (private pharmacy; as of 2024; varies by brand and region):

NLEM status:

• Sertraline is NOT included in NLEM 2022 (National List of Essential Medicines)

• NOT under NPPA price control (National Pharmaceutical Pricing Authority ceiling price not applicable)

• Pricing is market-driven; varies significantly between brands

Government supply:

• Limited availability in government hospitals and mental health institutions

• More commonly available: Fluoxetine, escitalopram (NLEM-listed antidepressants)

• Sertraline may be available in tertiary psychiatric hospitals (NIMHANS, state mental hospitals) but not reliably in primary health centers

Generic vs. branded:

• Generic sertraline significantly cheaper (₹2-3 per 50 mg tablet)

• Branded versions ₹5-8 per 50 mg tablet

• Bioequivalence generally acceptable for SSRIs; generic substitution reasonable for cost savings

Out-of-pocket cost for typical treatment:

• 50 mg/day for 1 month: ₹90-240 (branded), ₹60-90 (generic)

• 100 mg/day for 1 month: ₹150-360 (branded), ₹90-120 (generic)

• Long-term therapy (6-12 months): ₹540-4320 depending on dose and brand — significant burden for low-income patients; consider generic or switch to fluoxetine (NLEM-listed, cheaper) if cost barrier

Clinical pearls

1. Sertraline is preferred SSRI for cardiac patients

• Lower risk of QT prolongation compared to citalopram/escitalopram

• Can be used post-MI (depression common post-MI and worsens cardiac outcomes; SSRIs safe and beneficial)

• SADHART trial (Sertraline Antidepressant Heart Attack Randomized Trial): Demonstrated safety in post-MI patients

• Caution still needed with drug interactions (beta-blockers metabolized by CYP2D6 like metoprolol)

2. Start low in anxiety disorders to avoid activation

• Panic disorder, social anxiety: Start 25 mg/day × 1 week, then increase to 50 mg

• Initial anxiety/agitation ("jitteriness syndrome") occurs in 10-20% of anxious patients starting SSRI

• Usually transient (1-2 weeks) but can be distressing and lead to discontinuation

• Short-term benzodiazepine (clonazepam 0.25-0.5 mg BD for 2 weeks) can bridge this period, then taper as SSRI effect kicks in

• Educate patient in advance about possible initial worsening before improvement

3. Timing of dose: morning vs. evening — individualize

• Standard recommendation: Morning (to minimize insomnia risk)

• If patient experiences sedation: Switch to bedtime dosing

• If insomnia persists despite morning dosing: Address sleep hygiene, consider adding low-dose mirtazapine at night (also augments antidepressant effect) or trazodone (not available in India as monotherapy; combination product with sertraline banned)

• Consistent timing more important than specific time of day

4. Sexual dysfunction is dose-related and common — address proactively

• Incidence: 20-40% (likely underestimated; patients often don't volunteer)

• Ask specifically at each visit: "Any changes in sexual function, interest, or satisfaction?"

• Management options:

  • Wait and see: Sometimes improves after 2-3 months (tolerance develops)

  • Dose reduction: If clinically stable, try reducing from 100 mg to 50 mg

  • Drug holiday: Skip sertraline on weekends (not recommended — withdrawal risk, inconsistent dosing)

  • Add PDE-5 inhibitor: Sildenafil 25-50 mg PRN for erectile dysfunction (effective; safe combination)

  • Switch antidepressant: Mirtazapine (lower sexual dysfunction; weight gain risk), bupropion (NOT available in India), agomelatine (available in India, expensive)

  • Don't ignore: Sexual dysfunction is major cause of treatment discontinuation and relapse

5. Hyponatremia risk higher in elderly — monitor sodium

• Routine sodium check at weeks 2 and 4 in patients >65 years, especially if on diuretics

• Symptoms often non-specific (confusion, falls, weakness) and may be attributed to depression or aging

• Low threshold to check sodium if any new confusion, lethargy, or falls in elderly on sertraline

• If severe or recurrent, switch to mirtazapine (much lower SIADH risk)

6. Pregnancy and lactation: reassure and continue if needed

• Sertraline is one of best-studied and safest SSRIs in pregnancy

• Untreated maternal depression has clear fetal/neonatal risks (poor prenatal care, preterm birth, low birth weight, postpartum depression, impaired bonding)

• Benefits of treatment usually outweigh small risks

• Do not discontinue abruptly if patient becomes pregnant — gradual taper if stopping, or continue if moderate-severe depression

• Lactation: Very low infant exposure; preferred SSRI for breastfeeding mothers

• Coordinate care with obstetrician; document shared decision-making

7. Always taper when discontinuing — even if patient feels well

• Never stop abruptly (SSRI discontinuation syndrome common)

• Taper slowly: Reduce by 25-50 mg every 1-2 weeks

• Slower taper if on high dose (≥150 mg) or long duration (>1 year)

• Educate patient: Symptoms like dizziness, "brain zaps," flu-like symptoms are withdrawal (not relapse, not addiction) and resolve with slower taper

• If patient stops abruptly and develops withdrawal: Reinstate previous dose (symptoms resolve in 1-2 days), then taper properly

8. OCD requires higher doses and longer trials than depression

• Usual effective dose for OCD: 100-200 mg/day (vs. 50-100 mg for depression)

• Adequate trial: 10-12 weeks at 150-200 mg/day before declaring treatment failure (vs. 6-8 weeks for depression)

• Response often partial (30-50% symptom reduction); combine with cognitive-behavioural therapy (CBT) — exposure and response prevention (ERP) for optimal outcomes

• If inadequate response after adequate trial: Augment with antipsychotic (risperidone 1-2 mg, aripiprazole 5-10 mg) or switch to clomipramine (TCA; more effective for OCD but more side effects)

Tags

depression; SSRI; selective serotonin reuptake inhibitor; anxiety disorders; OCD; panic disorder; PTSD; psychiatry; pregnancy-compatible; lactation-compatible; cardiac-safe; Schedule H India; mental health

Version

RxIndia v0.2—18 May 2025

References

1. CDSCO (Central Drugs Standard Control Organisation):

   • Sertraline hydrochloride product inserts (various manufacturers registered in India)

   • Approved indications: Major depressive disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder

2. Indian Pharmacopoeia 2018 — Sertraline Hydrochloride monograph

3. NLEM 2022 (National List of Essential Medicines) — Ministry of Health & Family Welfare, Government of India

   • Note: Sertraline NOT included in NLEM 2022; fluoxetine and escitalopram are listed SSRIs

4. API Textbook of Medicine, 11th Edition — Psychiatry section: Depression, anxiety disorders, OCD management

5. AIIMS Psychiatry Protocols — Department of Psychiatry, All India Institute of Medical Sciences, New Delhi

   • Management of depression, anxiety disorders, OCD

   • SSRI use in special populations

6. Indian Psychiatric Society (IPS) Guidelines:

   • Clinical Practice Guidelines for Management of Depression (2017)

   • Use of antidepressants in pregnancy and lactation

7. ICMR (Indian Council of Medical Research):

   • National Mental Health Programme guidelines

   • Standard Treatment Workflows for depression

8. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 13th Edition — Antidepressants, SSRIs pharmacology

9. Harrison's Principles of Internal Medicine, 21st Edition — Mental health disorders, depression and anxiety management

10. International Guidelines (for context, off-label uses marked clearly):

    • NICE (UK) Guidelines: Depression in adults, OCD, PTSD

    • American Psychiatric Association (APA) Practice Guidelines

    • SADHART Trial (Sertraline Antidepressant Heart Attack Randomized Trial) — Glassman et al., JAMA 2002 — safety in post-MI depression

11. LactMed (Drugs and Lactation Database) — NIH; sertraline compatibility with breastfeeding (supportive reference; India-specific data prioritized)

12. Pharmacovigilance Programme of India (PvPI) — adverse event reporting for sertraline

Last updated
20/11/2025